Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 38 entries
View as:

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04934124 Org: User:
Start: 12/23/20 End: 08/23/21 Due: 08/23/22

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

Phase: N/A Priority: Normal
NCT ID: NCT06651567 Org: User:
Start: 10/22/24 End: 11/30/27 Due: 11/30/28

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

Phase: N/A Priority: Normal
NCT ID: NCT06372964 Org: User:
Start: 05/13/24 End: 05/31/27 Due: 05/31/28

Study of Lumateperone in the Treatment of Patients With Bipolar Mania

Phase: N/A Priority: Normal
NCT ID: NCT06462612 Org: User:
Start: 07/17/24 End: 06/30/26 Due: 06/30/27

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

Phase: N/A Priority: Normal
NCT ID: NCT06480383 Org: User:
Start: 08/05/24 End: 06/30/27 Due: 06/30/28

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

Phase: N/A Priority: Normal
NCT ID: NCT06706674 Org: User:
Start: 12/06/24 End: 04/30/27 Due: 04/30/28

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

Phase: N/A Priority: Normal
NCT ID: NCT02600507 Org: User:
Start: 03/07/16 End: 07/02/20 Due: 07/02/21

ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02817906 Org: User:
Start: 08/29/16 End: 01/30/19 Due: 01/30/20

Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

Phase: N/A Priority: Normal
NCT ID: NCT06627413 Org: User:
Start: 08/23/24 End: 03/31/26 Due: 03/31/27

A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06786286 Org: User:
Start: 01/28/25 End: 03/26/25 Due: 03/26/26

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

Phase: N/A Priority: Normal
NCT ID: NCT06462586 Org: User:
Start: 06/19/24 End: 04/30/26 Due: 04/30/27

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT05061719 Org: User:
Start: 10/08/21 End: 10/23/24 Due: 10/23/25

Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression

Phase: N/A Priority: Normal
NCT ID: NCT02600494 Org: User:
Start: 12/15/15 End: 07/24/19 Due: 07/24/20

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia or Bipolar Disorder

Phase: N/A Priority: Normal
NCT ID: NCT06229210 Org: User:
Start: 01/25/24 End: 12/31/27 Due: 12/31/28

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03257046 Org: User:
Start: 09/28/17 End: 09/28/18 Due: 09/28/19

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT05850689 Org: User:
Start: 05/02/23 End: 10/31/26 Due: 10/31/27

A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02469155 Org: User:
Start: 06/30/15 End: 08/31/16 Due: 08/31/17

A Trial to Assess the Antipsychotic Efficacy of ITI-007

Phase: N/A Priority: Normal
NCT ID: NCT02282761 Org: User:
Start: 11/30/14 End: 09/30/15 Due: 09/30/16

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT04959032 Org: User:
Start: 07/08/21 End: 08/07/24 Due: 08/07/25

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Phase: N/A Priority: Normal
NCT ID: NCT06701903 Org: User:
Start: 11/21/24 End: 06/30/27 Due: 06/30/28

Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT04709224 Org: User:
Start: 12/30/20 End: 05/23/22 Due: 05/23/23

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT04985942 Org: User:
Start: 07/30/21 End: 02/27/24 Due: 02/27/25

Study of a Novel Antipsychotic ITI-007 in Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT01499563 Org: User:
Start: 12/31/11 End: 11/30/13 Due: 11/30/14

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

Phase: N/A Priority: Normal
NCT ID: NCT03249376 Org: User:
Start: 11/27/17 End: 03/01/19 Due: 03/01/20

Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05766813 Org: User:
Start: 03/13/23 End: 10/31/25 Due: 10/31/26